प्यार करना बहुत ही सहज है, जैसे कि ज़ुल्म को झेलते हुए ख़ुद को लड़ाई के लिए तैयार करना. -पाश
Saturday, July 30, 2016
Sunday, July 24, 2016
Puppetry
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sunday, July 17, 2016
क्या करूँ संवेदना लेकर तुम्हारी / हरिवंशराय बच्चन
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
मैं दुखी जब-जब हुआ
संवेदना तुमने दिखाई,
मैं कृतज्ञ हुआ हमेशा,
रीति दोनो ने निभाई,
किन्तु इस आभार का अब
हो उठा है बोझ भारी;
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
एक भी उच्छ्वास मेरा
हो सका किस दिन तुम्हारा?
उस नयन से बह सकी कब
इस नयन की अश्रु-धारा?
सत्य को मूंदे रहेगी
शब्द की कब तक पिटारी?
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
कौन है जो दूसरों को
दु:ख अपना दे सकेगा?
कौन है जो दूसरे से
दु:ख उसका ले सकेगा?
क्यों हमारे बीच धोखे
का रहे व्यापार जारी?
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
क्यों न हम लें मान, हम हैं
चल रहे ऐसी डगर पर,
हर पथिक जिस पर अकेला,
दुख नहीं बँटते परस्पर,
दूसरों की वेदना में
वेदना जो है दिखाता,
वेदना से मुक्ति का निज
हर्ष केवल वह छिपाता;
तुम दुखी हो तो सुखी मैं
विश्व का अभिशाप भारी!
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
क्या करूँ?
मैं दुखी जब-जब हुआ
संवेदना तुमने दिखाई,
मैं कृतज्ञ हुआ हमेशा,
रीति दोनो ने निभाई,
किन्तु इस आभार का अब
हो उठा है बोझ भारी;
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
एक भी उच्छ्वास मेरा
हो सका किस दिन तुम्हारा?
उस नयन से बह सकी कब
इस नयन की अश्रु-धारा?
सत्य को मूंदे रहेगी
शब्द की कब तक पिटारी?
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
कौन है जो दूसरों को
दु:ख अपना दे सकेगा?
कौन है जो दूसरे से
दु:ख उसका ले सकेगा?
क्यों हमारे बीच धोखे
का रहे व्यापार जारी?
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
क्यों न हम लें मान, हम हैं
चल रहे ऐसी डगर पर,
हर पथिक जिस पर अकेला,
दुख नहीं बँटते परस्पर,
दूसरों की वेदना में
वेदना जो है दिखाता,
वेदना से मुक्ति का निज
हर्ष केवल वह छिपाता;
तुम दुखी हो तो सुखी मैं
विश्व का अभिशाप भारी!
क्या करूँ संवेदना लेकर तुम्हारी?
क्या करूँ?
Saturday, July 16, 2016
Shah Faesal's Post
By juxtaposing my photos with the images of a slain militant commander, a section of national media has once again fallen back upon its conventional savagery that cashes on falsehoods, divides people and creates more hatred.
At a moment when Kashmir is mourning its dead, the propaganda and provocation being dished out from red and blue newsrooms is breeding more alienation and anger in Kashmir than what Indian state can manage.
Personal vulnerability apart, the very fact of becoming a part of a ridiculous debate is something which has disturbed me very much. Have I joined IAS to do a job or to become a part of your sadistic propaganda machine? In fact when I qualified this exam I never thought of spending my whole life scratching the desk and if this nonsense around me continues, I might prefer to resign sooner than later.
I am adding to what my younger colleague Yasin Chaudhary had said earlier in his Facebook post. ZeeNews Aaj Tak TimesNow and NewsX are not going to tell you the truth about Kashmir. Please mind your head.
No Government would want to hurt it's people and when a state kills and maims it's own citizens, it's self-injury and self-decimation of the worst sort, it makes the body-politic bleed as well. So no Government can distance itself from the pain of it's people and all out efforts are being made to contain this crisis and reach out to youth. It is going to take time.
Till then we have to steer safe from spoilers who want to set Kashmir valley on fire just for the sake of TRP.
Let's pray for those who lost their lives and their eyesight in the ongoing turmoil in Kashmir and stand by one another in this moment of truth. I didn't have net access all this while and today once I saw my timeline, I realised it was the time to speak up. Inalillahi wa Ina-ilaihi rajioon.
Pradhan Mantri Rojgar Protsahan Yojana
- Launched in Union Budget 2016-17, it is a pension scheme contribution in a bid to create more formal sector jobs
- The scheme will be applicable for the new employees, earning Rs.15,000 a month, who have worked for 240 days during a year in an establishment
- About 3.5 lakh establishments, which hire more than 20 workers, will be covered under the scheme
- Govt will pay 8.33% of wages to Employees Pension Scheme (EPS) on behalf of employers for workers during first three years of employment
- For this, an allocation of Rs.1,000 crore had been made in the Budget
- Reimbursement: The payment of the EPS contribution will be in the form of reimbursements to employers
- Regulatory fear: It will increase regulation in the labour market which firms would not prefer as there will be increased scrutiny of their books
Rashtriya Mahila Kosh | Ministry of Women and Child Development
RMK extends microfinance to the poorest and asset less women entrepreneurs through Intermediatroy Organisations (IMOs) for income generating activities @ 6% simple interest who in turn extend the loan to SHGs beneficiaries’ upto 14% simple rate of interest.
The existing mechanism for effective implementation of various schemes of RMK is as under:
i. On receipt of any loan application from the NGOs, a preliminary appraisal is made. If any additional documents/ information is required from the applicant side, a query letter is raised. After receipt of full set of documents, the loan is then appraised.
ii. At this stage, a decision is taken as to either refer it for pre-sanction study by the RMK officials or to decline the proposal.
iii. For those proposals which meet all the eligible criteria framed by RMK and after receipt of all required documents / information, a pre-sanction study is conducted by RMK officials.
iv. During such pre-sanction study, the RMK Officers visit the organization, check all the books and registers such as Cash Book, General Ledger, Vouchers etc. They also visit the Self-Help Groups (SHGs) promoted by the organization, interact with SHG members. Based on the feedback / information collected during the field visit, the officers prepare the Pre-sanction study report.
v. After this report, an appraisal note is prepared by the concerned Deputy Director for placing the same before the Competent Authority.
vi. The Competent Authority, after considering all the relevant facts of the case as contained in the Appraisal note, sanctions or defers the proposal for submission of further details or declines it. The applicant NGOs is conveyed the decision of the Competent Authority.
vii. After sanction of the loan by the Committee, RMK conveys the sanction to the NGOs containing all terms & conditions of the sanction.
viii. On receipt of necessary documents viz. disbursement certificate, utilization certificate, etc., the post-sanction monitoring study is conducted by the RMK officers (other than the one who had under taken the pre-sanction visit) to verify the end use of the funds, adherence to the terms & conditions of the sanction letter and quality of utilization of funds.
ix. During the Post Sanction Visit, RMK officials verify the related records, entries in books etc.
x. The women SHGs benefited out of the 1st installment of loan are also visited at random by RMK officials to verify the assets created out of RMK loan. In case of misutilization / misappropriation, RMK can also recall the loan.
xi. If the borrowers default, necessary legal action under Section 138 of Negotiable Instrumental Act, filling of Civil Suit and other recovery proceeding through appointment of Arbitrator are taken. Simultaneously the defaulting NGOs are blacklisted whereby they are debarred from availing any sort of grants or aid by any Central / State Government agency.
This information was given by the Union Minister of Women and Child Development, Smt Maneka Sanjay Gandhi in reply to a starred question in the Lok Sabha today
The existing mechanism for effective implementation of various schemes of RMK is as under:
i. On receipt of any loan application from the NGOs, a preliminary appraisal is made. If any additional documents/ information is required from the applicant side, a query letter is raised. After receipt of full set of documents, the loan is then appraised.
ii. At this stage, a decision is taken as to either refer it for pre-sanction study by the RMK officials or to decline the proposal.
iii. For those proposals which meet all the eligible criteria framed by RMK and after receipt of all required documents / information, a pre-sanction study is conducted by RMK officials.
iv. During such pre-sanction study, the RMK Officers visit the organization, check all the books and registers such as Cash Book, General Ledger, Vouchers etc. They also visit the Self-Help Groups (SHGs) promoted by the organization, interact with SHG members. Based on the feedback / information collected during the field visit, the officers prepare the Pre-sanction study report.
v. After this report, an appraisal note is prepared by the concerned Deputy Director for placing the same before the Competent Authority.
vi. The Competent Authority, after considering all the relevant facts of the case as contained in the Appraisal note, sanctions or defers the proposal for submission of further details or declines it. The applicant NGOs is conveyed the decision of the Competent Authority.
vii. After sanction of the loan by the Committee, RMK conveys the sanction to the NGOs containing all terms & conditions of the sanction.
viii. On receipt of necessary documents viz. disbursement certificate, utilization certificate, etc., the post-sanction monitoring study is conducted by the RMK officers (other than the one who had under taken the pre-sanction visit) to verify the end use of the funds, adherence to the terms & conditions of the sanction letter and quality of utilization of funds.
ix. During the Post Sanction Visit, RMK officials verify the related records, entries in books etc.
x. The women SHGs benefited out of the 1st installment of loan are also visited at random by RMK officials to verify the assets created out of RMK loan. In case of misutilization / misappropriation, RMK can also recall the loan.
xi. If the borrowers default, necessary legal action under Section 138 of Negotiable Instrumental Act, filling of Civil Suit and other recovery proceeding through appointment of Arbitrator are taken. Simultaneously the defaulting NGOs are blacklisted whereby they are debarred from availing any sort of grants or aid by any Central / State Government agency.
This information was given by the Union Minister of Women and Child Development, Smt Maneka Sanjay Gandhi in reply to a starred question in the Lok Sabha today
Thursday, July 14, 2016
लौ-ए-दिल जला दूँ क्या / जॉन एलिया
फारेहा निगारिना, तुमने मुझको लिखा है
"मेरे ख़त जला दीजे !
मुझको फ़िक्र रहती है !
आप उन्हें गँवा दीजे !
आपका कोई साथी, देख ले तो क्या होगा !
देखिये! मैं कहती हूँ ! ये बहुत बुरा होगा !"
मैं भी कुछ कहूँ तुमसे,
फारेहा निगारिना
ए बनाजुकी मीना
इत्र बेज नसरीना
रश्क-ए-सर्ब-ए-सिरमीना
मैं तुम्हारे हर ख़त को लौह-ए-दिल समझता हूँ !
लौह-ए-दिल जला दूं क्या ?
जो भी सत्र है इनकी, कहकशां है रिश्तों की
कहकशां लुटा दूँ क्या ?
जो भी हर्फ़ है इनका, नक्श-ए-जान है जनानां
नक्श-ए-जान मिटा दूँ क्या ?
है सवाद-ए-बीनाई, इनका जो भी नुक्ता है
मैं उसे गंवा दूँ क्या ?
लौह-ए-दिल जला दूँ क्या ?
कहकशां लुटा दूँ क्या ?
नक्श-ए-जान मिटा दूँ क्या ?
मुझको लिख के ख़त जानम
अपने ध्यान में शायद
ख्वाब ख्वाब ज़ज्बों के
ख्वाब ख्वाब लम्हों में
यूँ ही बेख्यालाना
जुर्म कर गयी हो तुम
और ख्याल आने पर
उस से डर गयी हो तुम
जुर्म के तसव्वुर में
गर ये ख़त लिखे तुमने
फिर तो मेरी राय में
जुर्म ही किये तुमने
जुर्म क्यूँ किये जाएँ ?
ख़त ही क्यूँ लिखे जाएँ ?
"मेरे ख़त जला दीजे !
मुझको फ़िक्र रहती है !
आप उन्हें गँवा दीजे !
आपका कोई साथी, देख ले तो क्या होगा !
देखिये! मैं कहती हूँ ! ये बहुत बुरा होगा !"
मैं भी कुछ कहूँ तुमसे,
फारेहा निगारिना
ए बनाजुकी मीना
इत्र बेज नसरीना
रश्क-ए-सर्ब-ए-सिरमीना
मैं तुम्हारे हर ख़त को लौह-ए-दिल समझता हूँ !
लौह-ए-दिल जला दूं क्या ?
जो भी सत्र है इनकी, कहकशां है रिश्तों की
कहकशां लुटा दूँ क्या ?
जो भी हर्फ़ है इनका, नक्श-ए-जान है जनानां
नक्श-ए-जान मिटा दूँ क्या ?
है सवाद-ए-बीनाई, इनका जो भी नुक्ता है
मैं उसे गंवा दूँ क्या ?
लौह-ए-दिल जला दूँ क्या ?
कहकशां लुटा दूँ क्या ?
नक्श-ए-जान मिटा दूँ क्या ?
मुझको लिख के ख़त जानम
अपने ध्यान में शायद
ख्वाब ख्वाब ज़ज्बों के
ख्वाब ख्वाब लम्हों में
यूँ ही बेख्यालाना
जुर्म कर गयी हो तुम
और ख्याल आने पर
उस से डर गयी हो तुम
जुर्म के तसव्वुर में
गर ये ख़त लिखे तुमने
फिर तो मेरी राय में
जुर्म ही किये तुमने
जुर्म क्यूँ किये जाएँ ?
ख़त ही क्यूँ लिखे जाएँ ?
Wednesday, July 13, 2016
India Grants First Compulsory License to Generic Drug Producer
In a landmark move, the Indian Patent Office announced on Monday that it has issued its first compulsory license to a domestic generic drug-maker. The decision effectively ends German pharmaceutical company Bayer AG's monopoly over an anti-cancer drug and authorises the production of a low-cost version for the Indian market.
Compulsory licensing is when a government authorises a party other than the patent owner to produce the patented product or process, without the patent owner's consent.
New Delhi's decision may pave the way for other Indian generic producers to ask for compulsory licenses on patent-protected medicines if the right-holders fail to supply the products at affordable prices and in sufficient quantities. It could also potentially encourage other developing countries to use compulsory licensing for drugs for non-communicable diseases, which has until now mostly been limited to HIV drugs in these countries, experts say.
India is the world's third-largest pharmaceutical drug producer by volume; in 2011 the domestic pharmaceutical market reached a record of US$12.2 billion in sales. Patents on pharmaceutical products in India have been under the spotlight recently as Swiss drug manufacturer Novartis fights the rejection of a patent on another cancer drug on the grounds that it is not sufficiently innovative.
India only began issuing patents for drugs in 2005 in order to comply with the WTO's Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement). The TRIPS Agreement explicitly allows compulsory licensing as long as procedures and conditions set out in Article 31 of TRIPS are fulfilled.
Drug now poised to enter Indian market, patent office says
Under Section 84 (1) of the Indian Patent Act, any person may request a compulsory license if, after three years from the date of the grant of a patent, the needs of the public to be covered by the invention have not been satisfied; the invention is not available to the public at an affordable price; or the patented invention is not "worked in," or manufactured in the country, to the fullest extent possible.
Bayer acquired an importing license for Nexavar - the company's brand name for the drug sorafenib tosylate - in 2007; the patent on the drug was granted one year later. The company has claimed that Nexavar's sales in India were undermined by the marketing of a similar drug by another domestic generic producer, CIPLA, which it had sued for infringement.
According to the Indian Patent Office's decision, the German drug-maker did not begin importing the drug to India in 2008 and only small quantities were available during the following two years.
Bayer "took no adequate or reasonable steps to start the working of the invention in the territory of India on a commercial scale and to an adequate extent," the decision notes.
"The drug is exorbitantly priced and out of reach of most of the people," the patent authority wrote in its 62-page decision. "The product in question is not a luxury item but a lifesaving drug and it is highly important that a substantial part of the demand be met strictly. In the present case, even 1 percent of the public doesn't derive benefit of the patented drug."
In its compulsory license request, Indian generic manufacturer Natco proposed selling sorafenib tosylate at Rs. 8,800 per patient per month - approximately US $175 - resulting in a 97 percent price cut compared to Nexavar.
The compulsory license has been granted until 2020. Natco is not entitled to export the drug or to outsource its production.
The Indian Patent Office also said that Natco must pay royalties to Bayer on a quarterly basis at the rate of 6 percent of the net sales of the medicine, in accordance with remuneration guidelines set forth by the United Nations Development Programme.
Mixed response
Tido von Schoen-Angerer, Director of Médecins Sans Frontières' (MSF) Access Campaign, welcomed the announcement. "The decision marks a precedent that offers hope: it shows that new drugs under patent can also be produced by generic makers at a fraction of the price, while royalties are paid to the patent holder."
"This decision serves as a warning that when drug companies are price gouging and limiting availability, there is a consequence," added Michelle Childs, Director of Policy/Advocacy at the MSF Access Campaign.
For his part, Tapan Ray of the Organisation of Pharmaceutical Producers of India - an industry group of multi-national drug-makers - opposed the decision, saying that "the solution to helping patients with innovative medicines does not lie in breaking patents or denying patent rights to the innovators."
Bayer has the option of appealing the decision; the case could potentially reach the Indian Supreme Court.
ICTSD reporting; "Bayer mulls challenge to India cancer drug ruling," AFP, 13 March 2012; "India Grants First Compulsory Licence, For Bayer Cancer Drug," IP WATCH, 12 March 2012; "India's Supreme Court to Hear Dispute on Drug Patents," NEW YORK TIMES, 6 March 2012; "Analysis: India cancer ruling opens door for cheaper drugs," REUTERS, 13 March 2012.
Subscribe to:
Posts (Atom)
















